{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:02:57Z","timestamp":1785733377621,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T00:00:00Z","timestamp":1553299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12519-019-00242-6","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T06:03:51Z","timestamp":1553321031000},"page":"219-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy"],"prefix":"10.1007","volume":"15","author":[{"given":"Qing","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay N.","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Jay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Polari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Ciafaloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Griggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2203-1540","authenticated-orcid":false,"given":"Michele A.","family":"Gatheridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,23]]},"reference":[{"key":"242_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.23528","volume":"71","author":"JR Mendell","year":"2012","unstructured":"Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71:304\u201313.","journal-title":"Ann Neurol"},{"key":"242_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >\u200972,400 specimens. Eur J Hum Genet. 2012;20:27\u201332.","journal-title":"Eur J Hum Genet"},{"key":"242_CR3","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, Ottonello G, Chiarini Testa MB, Mastella C, Rava L, Bignamini E, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131:e1509\u201314.","journal-title":"Pediatrics"},{"key":"242_CR4","unstructured":"United States Food and Drug Administration. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm521263.htm (2016). Accessed 8 Jan 2019."},{"key":"242_CR5","unstructured":"United States Food and Drug Administration. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm534611.htm (2016). Accessed 8 Jan 2019."},{"key":"242_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/tnsci-2017-0001","volume":"8","author":"EW Ottesen","year":"2017","unstructured":"Ottesen EW. ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy. Transl Neurosci. 2017;8:1\u20136.","journal-title":"Transl Neurosci"},{"key":"242_CR7","unstructured":"Mendell JM. Precision genetic medicine for neuromuscular diseases. In: Proceedings of the world muscle society congress; 2018 Oct 3\u20136; Mendoza, Argentina."},{"key":"242_CR8","unstructured":"Mendell JM. Molecularly-based treatments for DMD. In: Proceedings of the fourth Qianjiang inherited birth defect (SMA\/DMD) forum 2018 March 16; Hangzhou, China."},{"key":"242_CR9","first-page":"CD003725","volume":"2016","author":"E Matthews","year":"2016","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;2016:CD003725.","journal-title":"Cochrane Database Syst Rev"},{"key":"242_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mus.23831","volume":"48","author":"RC Griggs","year":"2013","unstructured":"Griggs RC, Herr BE, Reha A, Elfring G, Atkinson L, Cwik V, et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve. 2013;48:27\u201331.","journal-title":"Muscle Nerve"},{"key":"242_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JND-170280","volume":"4","author":"Z Koeks","year":"2017","unstructured":"Koeks Z, Bladen CL, Salgado D, van Zwet E, Pogoryelova O, McMacken G, et al. Clinical outcomes in duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database. J Neuromuscul Dis. 2017;4:293\u2013306.","journal-title":"J Neuromuscul Dis"},{"key":"242_CR12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87:2123\u201331.","journal-title":"Neurology"},{"key":"242_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","volume":"86","author":"D Gloss","year":"2016","unstructured":"Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of duchenne muscular dystrophy: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016;86:465\u201372.","journal-title":"Neurology"},{"key":"242_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/mus.25089","volume":"54","author":"AM Connolly","year":"2016","unstructured":"Connolly AM, Florence JM, Zaidman CM, Golumbek PT, Mendell JR, Flanigan KM, et al. Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up. Muscle Nerve. 2016;54:681\u20139.","journal-title":"Muscle Nerve"},{"key":"242_CR15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/mus.24346","volume":"51","author":"AM Connolly","year":"2015","unstructured":"Connolly AM, Malkus EC, Mendell JR, Flanigan KM, Miller JP, Schierbecker JR, et al. Outcome reliability in non-ambulatory boys\/men with Duchenne muscular dystrophy. Muscle Nerve. 2015;51:522\u201332.","journal-title":"Muscle Nerve"},{"key":"242_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0960-8966(02)00180-3","volume":"12","author":"AM Connolly","year":"2002","unstructured":"Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2002;12:917\u201325.","journal-title":"Neuromuscul Disord"},{"key":"242_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","volume":"77","author":"DM Escolar","year":"2011","unstructured":"Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology. 2011;77:444\u201352.","journal-title":"Neurology"},{"key":"242_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cct.2017.04.008","volume":"58","author":"M Guglieri","year":"2017","unstructured":"Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, et al. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemp Clin Trials. 2017;58:34\u20139.","journal-title":"Contemp Clin Trials"},{"key":"242_CR19","unstructured":"Connolly A. Care of the boy with DMD in an era of molecularly-based treatments. In: Proceedings of the fourth Qianjiang inherited birth defect (SMA\/DMD) forum; 2018, Mar 15\u201317; Hangzhou, China; 2018."},{"key":"242_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26441","author":"AM Connolly","year":"2019","unstructured":"Connolly AM, Zaidman CM, Golumbek PT, Cradock MM, Flanigan KM, Kuntz NL, et al. Twice weekly glucocorticosteroids in infants and young boys with duchenne muscular dystrophy. Muscle Nerve. 2019. https:\/\/doi.org\/10.1002\/mus.26441 .","journal-title":"Muscle Nerve"},{"key":"242_CR21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","volume":"8","author":"M Kinali","year":"2009","unstructured":"Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009;8:918\u201328.","journal-title":"Lancet Neurol"},{"key":"242_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74:637\u201347.","journal-title":"Ann Neurol"},{"key":"242_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79:257\u201371.","journal-title":"Ann Neurol"},{"key":"242_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ajmg.a.30617","volume":"134","author":"KM Dent","year":"2005","unstructured":"Dent KM, Dunn DM, von Niederhausern AC, Aoyagi AT, Kerr L, Bromberg MB, et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A. 2005;134:295\u20138.","journal-title":"Am J Med Genet A"},{"key":"242_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50:477\u201387.","journal-title":"Muscle Nerve"},{"key":"242_CR26","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1489\u201398.","journal-title":"Lancet"},{"key":"242_CR27","unstructured":"European Medical Agencies. Tranlarna (ataluren): an overview of Translarna and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/translarna (2018). Accessed 8 Jan 2019."},{"key":"242_CR28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N Engl J Med. 2010;363:1429\u201337.","journal-title":"N Engl J Med"},{"key":"242_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/sj.mt.6300027","volume":"15","author":"MZ Salva","year":"2007","unstructured":"Salva MZ, Himeda CL, Tai PW, Nishiuchi E, Gregorevic P, Allen JM, et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther. 2007;15:320\u20139.","journal-title":"Mol Ther"},{"key":"242_CR30","unstructured":"Inacio P. Sarepta\u2019s gene therapy improves muscle function in 4 boys with DMD, phase 1\/2 trial shows. https:\/\/musculardystrophynews.com\/2018\/10\/12\/sarepta-dmd-gene-therapy-improves-muscle-function-4-boys-trial\/ (2018). Accessed 8 Jan 2019."},{"key":"242_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155\u201365.","journal-title":"Cell"},{"key":"242_CR32","doi-asserted-by":"publisher","first-page":"175628561875450","DOI":"10.1177\/1756285618754501","volume":"11","author":"V Parente","year":"2018","unstructured":"Parente V, Corti S. Advances in spinal muscular atrophy therapeutics. Ther Adv Neurol Disord. 2018;11:1756285618754501.","journal-title":"Ther Adv Neurol Disord"},{"key":"242_CR33","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med"},{"key":"242_CR34","unstructured":"Biogen. New data presented at MDA clinical conference show benefit in motor function for infants, teens, and young adults treated with Spinraza (Nusinersen). http:\/\/investors.biogen.com\/news-releases\/news-release-details\/new-data-presented-mda-clinical-conference-show-benefit-motor (2018). Accessed 8 Jan 2019."},{"key":"242_CR35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/hmg\/ddq514","volume":"20","author":"E Dominguez","year":"2011","unstructured":"Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet. 2011;20:681\u201393.","journal-title":"Hum Mol Genet"},{"key":"242_CR36","doi-asserted-by":"publisher","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","volume":"2","author":"CF Valori","year":"2010","unstructured":"Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med. 2010;2:35ra42.","journal-title":"Sci Transl Med"},{"key":"242_CR37","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322.","journal-title":"N Engl J Med"},{"key":"242_CR38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019;54:179\u201385.","journal-title":"Pediatr Pulmonol"},{"key":"242_CR39","unstructured":"Novartis. Novartis announces FDA filing acceptance and priority review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1. https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-fda-filing-acceptance-and-priority-review-avxs-101-one-time-treatment-designed-address-genetic-root-cause-sma-type-1 (2018). Accessed 8 Jan 2019."},{"key":"242_CR40","first-page":"1","volume":"2015","author":"MA Gatheridge","year":"2015","unstructured":"Gatheridge MA, Kwon JM, Mendell JM, Scheuerbrandt G, Moat SJ, Eyskens F, et al. Identifying non-duchenne muscular dystrophy-positive and false negative results in prior duchenne muscular dystrophy newborn screening programs: a review. JAMA Neurol. 2015;2015:1\u20137.","journal-title":"JAMA Neurol"},{"key":"242_CR41","unstructured":"Laing N\u00a0KB, Waddell L, Kreissl M, Douglas L, Wiley V. Newborn screening for duchenne muscular dystrophy in Australia. Abstract presented at: HGSA 2015. In: Proceedings of the human genetics society of Australasia annual scientific meeting, 8\u201311 Aug 2015, Perth, Australia."},{"key":"242_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12519-017-0036-3","volume":"13","author":"Q Ke","year":"2017","unstructured":"Ke Q, Zhao ZY, Griggs R, Wiley V, Connolly A, Kwon J, et al. Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment. World J Pediatr. 2017;13:197\u2013201.","journal-title":"World J Pediatr"},{"key":"242_CR43","unstructured":"Zhou Z. Updates in Zhejiang DMD NBS. In: Proceedings of the fourth Qianjiang inherited birth defect (SMA\/DMD) forum; 16\u201317 Mar 2018; Hangzhou, China; 2018."},{"key":"242_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:347\u201361.","journal-title":"Lancet Neurol"},{"key":"242_CR45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251\u201367.","journal-title":"Lancet Neurol"},{"key":"242_CR46","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018;17:445\u201355.","journal-title":"Lancet Neurol"},{"key":"242_CR47","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/mus.25185","volume":"54","author":"JM Kwon","year":"2016","unstructured":"Kwon JM, Abdel-Hamid HZ, Al-Zaidy SA, Mendell JR, Kennedy A, Kinnett K, et al. Clinical follow-up for duchenne muscular dystrophy newborn screening: a proposal. Muscle Nerve. 2016;54:186\u201391.","journal-title":"Muscle Nerve"},{"key":"242_CR48","unstructured":"Cure SMA. New York to implement newborn screening for sma October 1st. http:\/\/www.curesma.org\/news\/newyork-nbs-2018.html (2018). Accessed 8 Jan 2019."},{"key":"242_CR49","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/gim.2017.152","volume":"20","author":"JN Kraszewski","year":"2018","unstructured":"Kraszewski JN, Kay DM, Stevens CF, Koval C, Haser B, Ortiz V, et al. Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med. 2018;20:608\u201313.","journal-title":"Genet Med"},{"key":"242_CR50","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jpeds.2009.02.007","volume":"155","author":"E Ciafaloni","year":"2009","unstructured":"Ciafaloni E, Fox DJ, Pandya S, Westfield CP, Puzhankara S, Romitti PA, et al. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr. 2009;155:380\u20135.","journal-title":"J Pediatr"},{"key":"242_CR51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2015.06.002","volume":"53","author":"CW Lin","year":"2015","unstructured":"Lin CW, Kalb SJ, Yeh WS. Delay in diagnosis of spinal muscular atrophy: a systematic literature review. Pediatr Neurol. 2015;53:293\u2013300.","journal-title":"Pediatr Neurol"},{"key":"242_CR52","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.nmd.2017.02.010","volume":"27","author":"DN Wang","year":"2017","unstructured":"Wang DN, Wang ZQ, Yan L, He J, Lin MT, Chen WJ, et al. Clinical and mutational characteristics of Duchenne muscular dystrophy patients based on a comprehensive database in South China. Neuromuscul Disord. 2017;27:715\u201322.","journal-title":"Neuromuscul Disord"},{"key":"242_CR53","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mus.24880","volume":"53","author":"J Chung","year":"2016","unstructured":"Chung J, Smith AL, Hughes SC, Niizawa G, Abdel-Hamid HZ, Naylor EW, et al. Twenty-year follow-up of newborn screening for patients with muscular dystrophy. Muscle Nerve. 2016;53:570\u20138.","journal-title":"Muscle Nerve"},{"key":"242_CR54","first-page":"204","volume":"3","author":"EX Xu","year":"2015","unstructured":"Xu EX. Professor Shi-Wen Wu: One City, One Doctor-building up the national DMD registry network. Ann Transl Med. 2015;3:204.","journal-title":"Ann Transl Med"},{"key":"242_CR55","doi-asserted-by":"publisher","first-page":"e000854","DOI":"10.1136\/bmjgh-2018-000854","volume":"3","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhong L, Yuan S, van de Klundert J. Why patients prefer high-level healthcare facilities: a qualitative study using focus groups in rural and urban China. BMJ Glob Health. 2018;3:e000854.","journal-title":"BMJ Glob Health"},{"key":"242_CR56","first-page":"12","volume":"26","author":"A Campbell","year":"2011","unstructured":"Campbell A, Uren M. \u201cThe invisibles\u201d\u2026 Disability in China in the 21st century. Int J Spec Educ. 2011;26:12\u201324.","journal-title":"Int J Spec Educ"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-019-00242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12519-019-00242-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-019-00242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T03:23:14Z","timestamp":1606965794000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12519-019-00242-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,23]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["242"],"URL":"https:\/\/doi.org\/10.1007\/s12519-019-00242-6","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,23]]},"assertion":[{"value":"19 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ethical approval was not obtained since this is a literature review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Q. Ke, Z. Zhao, M. Baker, V. Wiley, J. M. Kwon, L. N. Alfano, C. Jay, E. Ciafaloni, M. Qi, M. A. Gatheridge: no financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article; J. R. Mendell: Dr. Mendell is a Consultant for Sarepta Therapeutics, Avexis (Novartis) therapeutics, and Exonics. He receives consulting fees but no salary. He is reimbursed for presenting clinical trials that pertain to the products sponsored by these companies. He also serves on the Scientific Advisory Boards of the companies. He has no interests from or investments in products that he tests in clinical trials; A. M. Connolly: Dr. Connolly is site principal investigator for multiple studies funded by industry (Sarepta, Avexis, Biogen, PTC Therapeutics, Pfizer, BMS, Fibrogen, Italafarma and NS Pharma). In the last 2\u00a0years, Dr. Connolly has served on advisory boards for Sarepta, Avexis, Genetech-Roche, Acceleron, Astelles, Mallincrodt, and SMA Foundation. She is also on the DMSB for Catabasis. Dr. Connolly does not have stock in any company; H. Polari: employee of PerkinElmer Inc; R. C. Griggs: Dr. Griggs has received a research grant support from Marathon, PTC and Sarepta Pharmaceuticals for work related to Duchenne muscular dystrophy. He is also supported by the U.S. National Institutes of Health, the Muscular Dystrophy Association and the Parent Project for Muscular Dystrophy for research on Duchenne muscular dystrophy. He consults for Solid Bioscience.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}